When I first spoke to Alan H. Bryce, M.D., I was immediately impressed with his intellect and his compassion. He cares deeply about people, and he also happens to be a remarkable smart scientist and oncologist. That combination is what every cancer patient hopes for.
Bryce joined City of Hope® Cancer Center Phoenix as the chief clinical officer in 2023 and is currently the Interim President of City of Hope Phoenix.
When we met, I was immediately impressed with both his intellect and his kindness. As a medical oncologist and researcher, he holds a dual title as professor of department of molecular medicine at Translational Genomics Research Institute (TGen), and City of Hope and located in Phoenix as an oncologist with City of Hope Cancer Center Phoenix.
Bryce focuses his practice on genitourinary cancers, primarily prostate and testicular cancers, with specialized expertise in cancer research and genomics in prostate cancer.
By analyzing a patient’s tumor at a molecular level, there is an opportunity to identify individually matched treatments that are not otherwise obvious in a given patient.
In collaboration with his colleagues at TGen, Dr. Bryce is at the forefront of cancer genomics and novel therapeutics for prostate cancer. His research focuses on cancer genetics, novel therapies and immunotherapeutic approaches in the search for a cure for prostate cancer.
Dr. Bryce studies the power of leveraging cancer genomics and believes we can treat each patient with the best drug for his individual situation.
He also gives all he can to bring the very best treatments to his patients.
After attending medical school at Finch University of Health Sciences/Chicago Medical School, Dr. Bryce completed a residency in internal medicine at Mayo Graduate School of Medicine, Mayo Clinic College of Medicine.
He then finished medical training as chief resident in his hematology and medical oncology fellowship at Mayo Graduate School of Medicine, Mayo Clinic College of Medicine.
Throughout his career, Dr. Bryce has been widely published and received numerous honors and awards. He is board certified in internal medicine, hematology and medical oncology and is a member of several professional organizations, including the American Association of Clinical Oncology (ASCO), and is the genitourinary chair for Academic and Community Cancer Research United.
The City of Hope hospitals and facilities are in a class by themselves. Not only are they brilliant and highly trained, they are also truly compassionate. Compassion goes a very long way when you are a cancer oncologist.
I am alive because of a group of doctors at the Hope City of Hope® Cancer Centers Southern California along with my hope hospital UDCD, another organization that brings true care and the most cutting-edge treatments to patients.
Since joining City of Hope Phoenix in 2023 as Chief Clinical Officer, Dr. Bryce has been a catalyst for transformation, bringing deep clinical expertise, steady leadership, and a passion for improving the lives of people facing cancer.
A nationally recognized oncologist and researcher, he also serves as a professor at the Translational Genomics Research Institute (TGen), part of City of Hope.
Specifically in Arizona, Bryce and his colleagues have demonstrably helped change the hospital landscape by bringing more state of-the-art technologies and kind doctors and scientists.
As an oncologist with City of Hope Cancer Center Phoenix, Dr. Bryce focuses his practice on genitourinary cancers, primarily prostate and testicular cancers, with specialized expertise in cancer research and genomics in prostate cancer.
By analyzing a patient’s tumor at a molecular level, there is an opportunity to identify individually matched treatments that are not otherwise obvious in a given patient.
In collaboration with his colleagues at TGen, Dr. Bryce is at the forefront of cancer genomics and novel therapeutics for prostate cancer. His research focuses on cancer genetics, novel therapies and immunotherapeutic approaches in the search for a cure for prostate cancer.
Dr. Bryce studies the power of leveraging cancer genomics and believes we can treat each patient with the best drug for his individual situation.
A nationally recognized oncologist and researcher, he also serves as a professor at the Translational Genomics Research Institute (TGen), part of City of Hope.
After attending medical school at Finch University of Health Sciences/Chicago Medical School, Dr. Bryce completed a residency in internal medicine at Mayo Graduate School of Medicine, Mayo Clinic College of Medicine.
He then finished medical training as chief resident in his hematology and medical oncology fellowship at Mayo Graduate School of Medicine, Mayo Clinic College of Medicine.
Throughout his career, Dr. Bryce has been widely published and received numerous honors and awards. He is board certified in internal medicine, hematology and medical oncology and is a member of several professional organizations, including the American Association of Clinical Oncology (ASCO), and is the genitourinary chair for Academic and Community Cancer Research United.
Dr. Bryce brings new, groundbreaking new technology and treatment options to the mainstream. It is fair to say that working with Bryce and his colleagues gives him an opportunity to work with some of the nation’s brightest best and brightest oncologists in the world.
But perhaps the best thing about Dr. Bryce is that he is a man who listens to his patients and his colleagues and really cares about them as people.
“In addition to the growth of the clinical practice, City of Hope has always been an organization with research as a core value,” Bryce says. “City of Hope was founded as a tuberculosis hospital outside of Los Angeles and from the beginning we worked to find a cure for tuberculosis. When that dream was successfully achieved through the discovery of antibiotics, we pivoted our resources into research to find cures for cancer and diabetes.”
Bryce added that this commitment has led to City of Hope making key discoveries. They include the development of the first synthetic human insulin and inventing the technology for antibody-based cancer therapies including Herceptin, Rituxan, and Avastin.
“Today our commitment to finding cures for cancer and diabetes are unchanged, and clinical trials are one part of that commitment,” he said. “In Arizona, we are committed to bringing the best cutting-edge trials to Arizona in order to make sure that our community has access to the best cancer care in the world without having to travel far from home.”
Photos courtesy of City of Hope® Cancer Center Phoenix
